Company intelligence / Profile preview

China NT Pharma Group

Shanghai, Shanghai, Chinantpharma.com ↗

Ownership: Private
Employees: ~22
Development stage: Other

Overview

China NT Pharma is conducting a Phase III clinical trial for its lead candidate "NT-1801" in osteoporosis. It has previously completed a Phase II study for "Uroacitides" in myelodysplastic syndrome and participated in a bioequivalence study of quetiapine fumarate tablets for bipolar disorder and schizophrenia. The company focuses on R&D as well as distribution of proprietary pharmaceutical products with an emphasis on bone health digital medicine platforms.

Therapeutic areas: PsychiatryEndocrinologyOncology
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

1 asset

uroacitide

Unknown

Beyond the preview

Go deeper on China NT Pharma Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China NT Pharma Group.

Explore the full profile